Empagliflozin adjunct with insulin pump therapy enhanced glycemic control and β-cell function in patients with long-standing type 2 diabetes

April 1, 2026AACE Endocrinology and DiabetesOpen Access

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research aims to evaluate the impact of empagliflozin combined with insulin pump therapy on glycemic control and β-cell function in long-standing type 2 diabetes.
Clinical evaluation of patients with long-standing type 2 diabetes receiving insulin pump therapy.
Assessment of glycemic control metrics before and after the addition of empagliflozin.
Analysis of β-cell function through relevant biomarkers.
Significant improvement in glycemic control observed in patients after empagliflozin introduction.
Enhanced β-cell function was noted alongside improved glycemic metrics.
The combination therapy indicated a positive effect on managing long-standing type 2 diabetes.

We only have this paper's title and publication details.

Answers are grounded in this paper and cite their sources.

Empagliflozin enhances glycemic control and β-cell function in type 2 diabetes, suggesting improved treatment strategies.

Empagliflozin adjunct with insulin pump therapy enhanced glycemic control and -cell

No takes yet. Share an insight, caveat, or question.

Su‐Yeon Choi (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share